An open label non randomised comparative interventional study to evaluate efficacy and safety of 2% Crisaborole ointment versus 0.05% Clobetasol propionate ointment in mild alopecia areata at a tertiary care centre

•All patients of age group 18 to 60 years with clinically diagnosed cases of Alopecia Areata, with one than one patch of hair loss attending Kle’s Dr. Prabhakar Kore Hospital will be chosen.

•Informed consent will be taken from all the patients included in the study.

•All patients will undergo a detailed history taking, general, physical, systemic and dermatological examination.

•Data will be collected by a single examiner and recorded in case record proforma.

•Patients will be explained in terms of the treatment offered in terms of expected results, duration of treatment, follow-ups, side effects to be reported and prognosis of the treatment.

•Digital photographs from all sides of the scalp will be taken using identical camera settings, patients positioning and room lighting at baseline and at every sitting.

•INTERVENTION DONE - The patients are given topical 2% Crisaborole ointment twice daily application on one  patch and 0.05% Clobetasol propionate ointment twice daily on another patch.

•The patients will be called after 1 month to assess the effectiveness of both topical medications and change from the baseline

•The patients are called after every month for a total period of 3 months.

•After 3 months, digital photographs will be compared with that at the baseline.

•Physicians  assessment of improvement will be done by alopecia areata physician global assessment score.

•Patients assessment of improvement will be recorded by VISUAL ANALOG SCALE.

•The efficacy of treatment will be calculated based on percentage of hair regrowth.

•The safety of treatment will be assessed by the side effects associated with the treatment.